Share Email Print
cover

Proceedings Paper

Preliminary investigation into the use of diffuse optical tomography for monitoring and imaging stroke
Author(s): David A. Boas; Thomas J. Gaudette; Lai Wang; Hakan Ay; Walter Koroshetz; Gregory Sorensen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

For patients with ischemic stroke there is benefit to early treatment (within 3 hours) with recombinant tissue plasminogen activator, rt-PA, an FDA approved thrombolytic drug. The use of rt-PA within the first 3 hours of an ischemic stroke is based upon a clinical trial showing an increased probability of good functional recovery in the treated group. The challenge is now to individualize therapy in order to decrease the degree of permanent brain injury due to ischemia in as many patients as possible. This requires new tools to assay brian flood flow and tissue injury. However, there is currently no means to non-invasively monitor brain perfusion. There is no non-invasive method to determine whether administration of thrombolytic drug in an individual patient is actually effective in causing reperfusion. We have developed such a method based on using light in conjunction with periodic bolus injections of an optical vascular contrast agent to continuously monitor brain perfusion non-invasively.

Paper Details

Date Published: 13 July 1999
PDF: 6 pages
Proc. SPIE 3712, Battlefield Biomedical Technologies, (13 July 1999); doi: 10.1117/12.353023
Show Author Affiliations
David A. Boas, Harvard Medical School (United States)
Thomas J. Gaudette, Harvard Medical School (United States)
Lai Wang, Tufts Univ. (United States)
Hakan Ay, Harvard Medical School (United States)
Walter Koroshetz, Harvard Medical School (United States)
Gregory Sorensen, Harvard Medical School (United States)


Published in SPIE Proceedings Vol. 3712:
Battlefield Biomedical Technologies
Homer H. Pien, Editor(s)

© SPIE. Terms of Use
Back to Top